Improving the power of diagnostics in the era of targeted therapy and personalized healthcare

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 2, 2010, Pages 226-234

  Walk, Eric E ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Molecular diagnostic; Personalized healthcare; Targeted therapy

Indexed keywords

ABACAVIR; BEXAROTENE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; GEFITINIB; GENE PRODUCT; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TRANSCRIPTION FACTOR ERG; TRASTUZUMAB; VANDETANIB;

BIOMEDICAL TECHNOLOGY ASSESSMENT; BREAST CANCER; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC PROCEDURE; DRUG RESPONSE; DRUG TARGETING; GENE MUTATION; GOOD LABORATORY PRACTICE; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; LABORATORY DIAGNOSIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; MUTATIONAL ANALYSIS; NEOPLASM; PRACTICE GUIDELINE; REIMBURSEMENT; REVIEW; STANDARDIZATION; TUMOR CELL;

DRUG DESIGN; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASMS; PATHOLOGY, MOLECULAR; PERSONAL HEALTH SERVICES; PHARMACOGENETICS; REIMBURSEMENT MECHANISMS;

EID: 77749251974     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. De Leon J: AmpliChip CYP450 test: Personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn (2006) 6(3): 277-286.
2. Engell HC: Cancer cells in the circulating blood; a clinical study on the occurrence of cancer cells in the peripheral blood and in venous blood draining the tumour area at operation. Acta Chir Scand Suppl (1955) 201(Suppl):1-70.
3. Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specifc biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 8(5):329-340.
4. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D: Circulating tumor cells predict survival beneft from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14(19):6302-6309.
5. Pantel K, Alix-Panabieres C, Riethdorf S: Cancer micrometastases. Nat Rev Clin Oncol (2009) 6(6):339-351.
6. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 310(5748):644-648.
7. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, et al: Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res (2009) 15(14):4706-4711.
8. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, et al: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 69(7):2912-2918.
9. Wulfng P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, Brandt B: HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res (2006) 12(6):1715-1720.
10. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to geftinib and erlotinib. Proc Natl Acad Sci USA (2004) 101(36):13306-13311.
11. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K et al: EGFR mutations in lung cancer: Correlation with clinical response to geftinib therapy. Science (2004) 304(5676):1497-1500.
12. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teague JW, et al: COSMIC (the Catalogue of Somatic Mutations in Cancer): A resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2010) 38:D652-D657.
13. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H: Acquired resistance of lung adenocarcinomas to geftinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 2(3):e73.
14. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, et al: MET amplifcation leads to geftinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 316(5827): 1039-1043.
15. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 26(3):374-379.
16. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C Rougier P: KRAS status and effcacy in the frst-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol (2008) 26(15S):2.
17. 600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (2009) 27(15S):9000.
18. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, et al: Identifcation of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 448(7153):561-566.
19. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, et al: EML4-ALK fusion gene and effcacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 14(13):4275-4283.
20. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 27(26):4247-4253.
21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to geftinib. N Engl J Med (2004) 350(21):2129-2139.
22. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, et al: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 359(4):366-377.
23. Helzer KT, Barnes HE, Day L, Harvey J, Billings PR, Forsyth A: Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model. Cancer Res (2009) 69(19):7860-7866.
24. The Cancer Genome Atlas Project: NCI, Bethesda, MD, USA (2009). cancergenome.nih.gov
25. International Cancer Genome Consortium: International Cancer Genome Consortium (2009). www.icgc.org
26. COSMIC-Catalogue of Somatic Mutations in Cancer: The Sanger Institute, Cambridge, UK (2009). www.sanger.ac.uk/cosmic
27. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R, et al: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 91(2):355-358.
28. Macconaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L et al: Profling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 4(11):e7887.
29. Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, et al: Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 12(7):852-855.
30. Compton C: Getting to personalized cancer medicine: Taking out the garbage. Cancer (2007) 110(8):1641-1643.
31. Narayanan S: Considerations in the application of selected molecular biology techniques in the clinical laboratory: Preanalytical and analytical issues. Rinsho Byori (1996) 103(Suppl 103):262-270.
32. Lippi G, Guidi GC, Mattiuzzi C, Plebani M: Preanalytical variability: The dark side of the moon in laboratory testing. Clin Chem Lab Med (2006) 44(4):358-365.
33. Ahmad S, Sundaramoorthy E, Arora R, Sen S, Karthikeyan G, Sengupta S: Progressive degradation of serum samples limits proteomic biomarker discovery. Anal Biochem (2009) 394(2): 237-242.
34. Spruessel A, Steimann G, Jung M, Lee SA, Carr T, Fentz AK, Spangenberg J, Zornig C, Juhl HH, David KA: Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques (2004) 36(6):1030-1037.
35. Oyama T, Ishikawa Y, Hayashi M, Arihiro K, Horiguchi J: The effects of fxation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer. Breast Cancer (2007) 14(2):182-188.
36. Khoury T, Sait S, Hwang H, Chandrasekhar R, Wilding G, Tan D, Kulkarni S: Delay to formalin fxation effect on breast biomarkers. Mod Pathol (2009) 22(11):1457-1467.
37. Blind C, Koepenik A, Pacyna-Gengelbach M, Fernahl G, Deutschmann N, Dietel M, Krenn V, Petersen I: Antigenicity testing by immunohistochemistry after tissue oxidation. J Clin Pathol (2008) 61(1):79-83.
38. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2007) 25(1):118-145. (Pubitemid 350003059)
39. Offce of Biorepositories and Biospecimen Research: NCI, Bethesda, MD, USA (2009). biospecimens.cancer.gov/default.asp
40. National Cancer Institute Best Practices for Biospecimen Resources: NCI, Bathesda, MD, USA (2007). biospecimens.cancer. gov/global/pdfs/NCI-Best- Practices-060507.pdf
41. Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P: Biomarker-driven early clinical trials in oncology: A paradigm shift for drug development. Cancer J (2009) 15(5): 406-420.
42. Simon R: The use of genomics in clinical trial design. Clin Cancer Res (2008) 14(19):5984-5993.
43. Kim ES, Herbst RS, Lee JJ, et al. Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. J Clin Oncol (2009) 27(15s):Abs 8024
44. Jiang W, Freidlin B, Simon R: Biomarker-adaptive threshold design: A procedure for evaluating treatment with possible biomarker-defned subset effect. J Natl Cancer Inst (2007) 99(13):1036-1043.
45. Freidlin B, Simon R: Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res (2005) 11(21):7872-7878.
46. Liu JP, Chow SC: Statistical issues on the diagnostic multivariate index assay for targeted clinical trials. J Biopharm Stat (2008) 18(1):167-182.
47. Akkari PA, Swanson TW, Crenshaw DG, Grossman I, Sundseth S, Burns DK, Roses AD: Pipeline pharmacogenetics: A novel approach to integrating pharmaco-genetics into drug development. Curr Pharm Des (2009) 15(32):3754-3763.
48. Javitt GH: In search of a coherent framework: Options for FDA oversight of genetic tests. Food Drug Law J (2007) 62(4): 617-652.
49. Pitts PJ: FDA and the critical path to twenty-frst-century medicine. J Med Philos (2008) 33(5):515-523.
50. de Leon J: Pharmacogenomics: The promise of personalized medicine for CNS disorders. Neuropsychopharmacology (2009) 34(1):159-172
51. ACCE Model Process for Evaluating Genetic Tests: CDC, Atlanta, GA, USA (2009). www.cdc.gov/genomics/gtesting/ACCE/index.htm
52. Innovation or stagnation: Challenge and opportunity on the critical path to new medical products: FDA, Silver Spring, MD, USA (2004). www.fda.gov/downloads/ScienceResearch/ SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ ucm113411.pdf
53. Innovation or stagnation: Critical path opportunities report and list: FDA, Silver Spring, MD, USA (2006). www.fda.gov/ohrms/ dockets/AC/07/briefing/ 2007-4329b-02-05-Critical%20Path%20 Report%202006.pdf
54. Woodcock J, Woosley R: The FDA critical path initiative and its infuence on new drug development. Annu Rev Med (2008) 59:1-12
55. Guidance for industry pharmacogenomic data submissions: FDA, Silver Spring, MD, USA (2005). www.fda.gov/downloads/ RegulatoryInformation/Guidances/ ucm126957.pdf
56. Drug-diagnostic co-development concept paper: FDA, Silver Spring, MD, USA (2005). www.fda.gov/downloads/Drugs/ ScienceResearch/ResearchAreas/ Pharmacogenetics/UCM116689.pdf
57. In vitro diagnostic multivariate index assays: FDA, Silver Spring, MD, USA (2007). www.fda.gov/downloads/MedicalDevices/ DeviceRegulationandGuidance/ GuidanceDocuments/ucm071455.pdf
58. Hughes B: Developing tools for stratifed medicine. Nat Rev Drug Discov (2009) 8(12):919-920.
59. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH, Geneva, Switzerland (2010). www.ich.org
60. ICH Topic E16-Genomic biomarkers related to drug response: Context, structure and format of qualifcation submissions: EMEA, London, UK (2009). www.ema.europa.eu/pdfs/human/ ich/38063609endraft.pdf
61. Davis JC, Furstenthal L, Desai AA, Norris T, Sutaria S, Fleming E, Ma P: The microeconomics of personalized medicine: Today's challenge and tomorrow's promise. Nat Rev Drug Discov (2009) 8(4):279-286.
62. Lai-Goldman M, Faruki H: Abacavir hypersensitivity: A model system for pharmacogenetic test adoption. Genet Med (2008) 10(12):874-878.
63. Ridge JR: Reimbursement and coverage challenges associated with bringing emerging molecular diagnostics into the personalized medicine paradigm. Personalized Med (2006) 3(3):345-348.
64. Meckley LM, Neumann PJ: Personalized medicine: Factors infuencing reimbursement. Health Policy (2009) 94(2):91-100.
65. Green C, Bryant J, Takeda A, Cooper K, Clegg A, Smith A, Stephens M: Bortezomib for the treatment of multiple myeloma patients. Health Technol Assess (2009) 13(Suppl 1):29-33.
66. Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M: Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess (2006) 10(34):iii-iv, ix-xi, 1-204.
67. Allred DC: Commentary: Hormone receptor testing in breast cancer: A distress signal from Canada. Oncologist (2008) 13(11):1134-1136.
68. Quality control for molecular diagnostics: QCMD, Glasgow, Scotland (2010). www.qcmd.org/index.php
69. Accreditation and laboratory improvement: CAP, Northfeld, IL, USA (2009). www.cap.org/apps/cap.portal?- nfpb=true&pageLabel=accreditation
70. United Kingdom National External Quality Assessment Service: UKNEQAS, Sheffeld, UK (2009). www.ukneqas.org.uk/ content/Pageserver.asp
71. Nordic Immunohistochemical Quality Control: NordiQC, Aalborg, Denmark (2009). www.nordiqc.org
72. Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom KJ, Nikiforova MN: The role of KRAS-mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med (2009) 133(10):1600-1606.